X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the licensing agreement, Recursion will be able to work on a new chemical compound for research and development purposes. This compound signifies a novel approach to treating fibrotic diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 04, 2024
Details:
The oncology-focused collaboration will leverage Bayer’s small molecule compound library and expertise in biology and medicinal chemistry as well as Recursion’s purpose-built artificial intelligence-guided drug discovery platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: $1,500.0 million Upfront Cash: $80.0 million
Deal Type: Collaboration November 09, 2023
Details:
Through the acquisition, Cyclica's two highly differentiated products in the digital chemistry space which will be integrated into the Recursion OS, including MatchMaker™, an AI-enabled deep learning engine that predicts the polypharmacology of small molecules and POEM™.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: Cyclica
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 08, 2023
Details:
Recursion intends to use the proceeds for general corporate purposes, which include advancing of existing clinical and preclinical programs, including it's new clinical program in AXIN1/APC mutant cancers with an initial focus in hepatocellular carcinoma and ovarian cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kinnevik AB
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 25, 2022
Details:
REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in FAP patients.
Lead Product(s): REC-4881
Therapeutic Area: Oncology Product Name: REC-4881
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
Recursion's conducting a dose optimization study in a sheep efficacy model of Tay-Sachs disease is prudent and in best interest of patients before enrolling infants in a Phase 2 trial of REC-3599 in ultra-rare indication infantile GM2 gangliosidosis.
Lead Product(s): REC-3599
Therapeutic Area: Genetic Disease Product Name: REC-3599
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022
Details:
Recursion will work with both Roche and Genentech's R&D units to leverage technology-enabled drug discovery through the Recursion Operating System to more rapidly identify novel targets and advance medicines in key areas of neuroscience as well as in an oncology indication.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $12,150.0 million Upfront Cash: $150.0 million
Deal Type: Collaboration December 07, 2021
Details:
REC-2282 is a potentially first-in-class, orally bioavailable, CNS-penetrant small molecule HDAC inhibitor being developed for the treatment of NF2-mutated meningiomas.
Lead Product(s): REC-2282
Therapeutic Area: Oncology Product Name: REC-2282
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce tumor size in FAP patients.
Lead Product(s): REC-4881
Therapeutic Area: Genetic Disease Product Name: REC-4881
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Details:
Proceeds from the financing will support the clinical development of Recursion’s therapeutic pipeline which is the broadest and deepest pipeline to date of any company operating within the space of digitally-powered drug discovery.
Lead Product(s): REC-994
Therapeutic Area: Genetic Disease Product Name: REC-994
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: $239.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing September 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
